|4.99|| +0.0895 / +1.83%|
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. Starpharma has three core development programs: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Melbourne, Australia.
|Jacinth K. Fairley||Chief Executive Officer & Executive Director|
|Nigel J. Baade||Chief Financial Officer & Secretary|
|David J. Owen||Vice President-Research|
|C. Paul Barrett||Vice President-Business Development|
|Tony Eglezos||Vice President-Business Development|